Market Place
Sourcing Support
NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179)
21 Feb 2024 //
BUSINESSWIRE
NorthSea Therapeutics to Present ICONA Phase 2b Data
10 Nov 2023 //
BUSINESSWIRE
NorthSea Receives FDA Rare Pediatric Disease Designation for SEFA-6179
17 Oct 2023 //
BUSINESSWIRE
NorthSea Therapeutics Provides Clinical Update Reflecting Progress Across NASH
05 Jan 2023 //
BUSINESSWIRE
NorthSea Initiates Phase 1 Trial of SEFA-6179 in orphan indication of IFALD
02 Feb 2022 //
BUSINESSWIRE
Biotech startup lines up more cash to steer its NASH drug through stormy seas
18 Dec 2021 //
ENDPTS
Icosabutate Phase 2b Interim Data Show Decrease in NASH & Fibrosis Biomarkers
16 Nov 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.